Fangsheng Pharmaceutical: The summary report of the Phase II clinical trial for Zhilong Tongluo tablets has been obtained
I'm PortAI, I can summarize articles.
Fangsheng Pharmaceutical announced that its research and development of the traditional Chinese medicine innovative drug Zhilong Tongluo Pian has obtained the Phase II clinical research report. This drug is suitable for various symptoms during the recovery period of cerebral infarction, and the trial results show good safety, as well as positive effects in improving neurological function and quality of life. It is recommended to continue with Phase III clinical research
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments